These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15870711

  • 1. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M.
    Br J Cancer; 2005 May 23; 92(10):1881-91. PubMed ID: 15870711
    [Abstract] [Full Text] [Related]

  • 2. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
    Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G.
    Exp Hematol; 2010 Jan 23; 38(1):27-37. PubMed ID: 19837126
    [Abstract] [Full Text] [Related]

  • 3. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.
    Oncogene; 2000 Jul 20; 19(31):3521-8. PubMed ID: 10918610
    [Abstract] [Full Text] [Related]

  • 4. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA, Laug WE, Sausville EA, Avramis VI.
    Cancer Chemother Pharmacol; 2003 Oct 20; 52(4):307-18. PubMed ID: 12827297
    [Abstract] [Full Text] [Related]

  • 5. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 20; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 6. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T.
    Leukemia; 2003 Jun 20; 17(6):999-1009. PubMed ID: 12764361
    [Abstract] [Full Text] [Related]

  • 7. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B, Tirnitz-Parker JE, Olynyk JK.
    Gastroenterology; 2008 Sep 20; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [Abstract] [Full Text] [Related]

  • 8. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 20; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

  • 9. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 10. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.
    Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp HP, Bokemeyer C, Kanz L, Brümmendorf TH.
    Exp Hematol; 2005 May 08; 33(5):542-9. PubMed ID: 15850831
    [Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M.
    J Invest Dermatol; 2004 Feb 08; 122(2):400-5. PubMed ID: 15009722
    [Abstract] [Full Text] [Related]

  • 12. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec 08; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
    Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, Yamamoto K, Ohyashiki K.
    Clin Cancer Res; 2002 Nov 08; 8(11):3341-7. PubMed ID: 12429620
    [Abstract] [Full Text] [Related]

  • 14. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 08; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 15. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.
    Int J Mol Med; 2004 Sep 01; 14(3):373-82. PubMed ID: 15289888
    [Abstract] [Full Text] [Related]

  • 17. Roots of imatinib resistance: a question of self-renewal?
    Burchert A.
    Drug Resist Updat; 2007 Sep 01; 10(4-5):152-61. PubMed ID: 17683977
    [Abstract] [Full Text] [Related]

  • 18. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V, Karampinas T, Voutsinas G, Roussidis AE, Papadopoulos S, Karamanos NK, Kletsas D.
    Mol Cancer Res; 2008 May 01; 6(5):706-14. PubMed ID: 18505916
    [Abstract] [Full Text] [Related]

  • 19. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 May 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 20. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 01; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.